Search results

Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune thrombocytopenia in adults.

Result type

Technology appraisal guidance

Last updated

26 October 2018

NICE was unable to make recommendations on eltrombopag (Revolade) for severe aplastic anaemia refractory to immunosuppressive therapy because no evidence submission was received from Novartis, but will review this decision if the company decides to make a submission

Result type

Technology appraisal guidance

Published

27 January 2016

Evidence-based recommendations on avatrombopag (Doptelet) for treating primary chronic immune thrombocytopenia in adults.

Result type

Technology appraisal guidance

Published

15 December 2022

Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making

Result type

Evidence summary

Published

21 October 2014

NICE recommends that research should be carried out to directly compare eltrombopag with non-thrombopoietin receptor agonist treatments...

Result type

Research recommendation

Published

9 June 2015

which collects data on the long-term outcomes of patients treated with eltrombopag and romiplostim. Any explanatory notes(if applicable)...

Result type

Research recommendation

Published

9 June 2015

Evidence-based recommendations on fostamatinib (Tavlesse) for chronic refractory chronic immune thrombocytopenia in adults.

Result type

Technology appraisal guidance

Published

19 October 2022

Discontinued [GID-TA10284]

Result type

Technology appraisal guidance

Status

Discontinued

This guidance has been updated and replaced by NICE technology appraisal guidance 293.

Result type

Technology appraisal guidance

Published

27 October 2010

NICE recommends that research should be carried out to directly compare eltrombopag with non-thrombopoietin receptor agonist treatments...